



**HAL**  
open science

## A Cohort Study on the Duration of Plasmodium falciparum Infections During the Dry Season in The Gambia

Katharine Collins, Sukai Ceesay, Sainabou Drammeh, Fatou Jaiteh, Marc-Antoine Guery, Kjerstin Lanke, Lynn Grignard, Will Stone, David Conway, Umberto D'alessandro, et al.

► **To cite this version:**

Katharine Collins, Sukai Ceesay, Sainabou Drammeh, Fatou Jaiteh, Marc-Antoine Guery, et al.. A Cohort Study on the Duration of Plasmodium falciparum Infections During the Dry Season in The Gambia. *Journal of Infectious Diseases*, In press, 10.1093/infdis/jiac116 . hal-03664364

**HAL Id: hal-03664364**

**<https://hal.umontpellier.fr/hal-03664364>**

Submitted on 10 May 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# A Cohort Study on the Duration of *Plasmodium falciparum* Infections During the Dry Season in The Gambia

Katharine A. Collins,<sup>1,2</sup> Sukai Ceasay,<sup>2,3</sup> Sainabou Drammeh,<sup>2</sup> Fatou K. Jaiteh,<sup>2</sup> Marc-Antoine Guery,<sup>3,4</sup> Kjerstin Lanke,<sup>1,2</sup> Lynn Grignard,<sup>4</sup> Will Stone,<sup>4,5</sup> David J. Conway,<sup>4,5</sup> Umberto D'Alessandro,<sup>2</sup> Teun Bousema,<sup>1,4,a</sup> and Antoine Claessens<sup>2,3,a</sup>

<sup>1</sup>Radboud university medical center, Radboud Institute for Health Sciences, Department of Medical Microbiology, Nijmegen, Netherlands, <sup>2</sup>Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia, <sup>3</sup>LPHI, MIVEGEC, Université de Montpellier, CNRS, INSERM, Montpellier, France, <sup>4</sup>Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom

**Background.** In areas where *Plasmodium falciparum* malaria is seasonal, a dry season reservoir of blood-stage infection is essential for initiating transmission during the following wet season.

**Methods.** In The Gambia, a cohort of 42 individuals with quantitative polymerase chain reaction-positive *P falciparum* infections at the end of the transmission season (December) were followed monthly until the end of the dry season (May) to evaluate infection persistence. The influence of human host and parasitological factors was investigated.

**Results.** A large proportion of individuals infected at the end of the wet season had detectable infections until the end of the dry season (40.0%; 16 of 40). At the start of the dry season, the majority of these persistent infections (82%) had parasite densities >10 p/μL compared to only 5.9% of short-lived infections. Persistent infections (59%) were also more likely to be multiclonal than short-lived infections (5.9%) and were associated with individuals having higher levels of *P falciparum*-specific antibodies ( $P = .02$ ).

**Conclusions.** Asymptomatic persistent infections were multiclonal with higher parasite densities at the beginning of the dry season. Screening and treating asymptomatic infections during the dry season may reduce the human reservoir of malaria responsible for initiating transmission in the wet season.

**Keywords.** dry season; malaria; multiplicity of infection; *Plasmodium falciparum*; transmission.

In many endemic areas, malaria transmission is seasonal, with most clinical cases occurring during the wet season. *Plasmodium falciparum* infections acquired during this period can persist in asymptomatic individuals throughout the dry season, and if they produce gametocytes, they can potentially contribute to transmission at the start of the next wet season [1–3]. These clinically silent infections can persist for many months without treatment [2], and they pose a significant hurdle for malaria elimination efforts [4]. Understanding how long infections persist in the dry season in The Gambia and identifying who carries them may inform targeted approaches to reduce the dry season reservoir of malaria and reduce reintroduction of malaria in the subsequent wet season.

Few studies have described the asymptomatic dry season reservoir of malaria and the related parasite and host factors.

Asymptomatic, genetically complex infections are common in high-transmission areas [5]; in addition, in low-transmission settings infections can persist for many months [6, 7]. The host-specific response to malaria infection may play an important role by allowing the establishment of chronic infections. Protection against severe malaria is acquired relatively quickly [8, 9], but the ability to control parasitemia at a subclinical levels develops more slowly after repeated exposure [10]. In Mali, individuals infected during the dry season had higher *P falciparum*-specific antibodies than those who were uninfected [11, 12], and older children were more likely to be infected at the end of the dry season compared to younger children [13]. Both findings support the hypothesis that a certain degree of exposure and immunity is required to be asymptotically infected. It is interesting to note that in Uganda, older children carried infections for a longer time than children under 5 and also adults [14], suggesting that the type of immune response associated with persistent asymptomatic infection may differ from responses that can clear infections [15]. Moreover, it is unclear whether parasite-specific antibody responses contribute to protection [16, 17] or are simply markers of previous exposure [18]. In a recent study, responses to a panel of *P falciparum* antigens indicated a higher level of immunity that allowed individuals to control blood-stage infections after controlled exposure to *P falciparum* sporozoites [19]. Other host factors may also play an important role in the establishment of chronic asymptomatic

Received 23 November 2021; editorial decision 28 March 2022; accepted 11 April 2022; published online 5 April 2022.

<sup>a</sup>T. B. and A. C. contributed equally to this work.

Correspondence: Antoine Claessens PhD, LPHI, Bat 24, Place Eugène Bataillon, 34095 Montpellier, France (antoine.claessens@umontpellier.fr).

The Journal of Infectious Diseases® 2022;XX:1–10

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com <https://doi.org/10.1093/infdis/jiac116>

infections. In Uganda, infections persisted longer in males than females [14]; host factors such as hemoglobinopathies [20] and anemia [21], known to be associated with the risk and severity of malaria, may also influence the duration of asymptomatic carriage [22].

Besides host factors related to chronic infections, parasites themselves may either be preprogrammed or adapted to persist throughout the dry, nontransmission season. Being able to establish a clinically silent infection that does not activate the immune system may result in a slower clearance rate, a plausible evolutionary strategy for surviving the dry season and ensuring onward transmission. In Mali, where malaria transmission is highly seasonal, parasite populations collected during the wet and dry seasons were similar. Nevertheless, parasites sampled in the dry season appeared to adapt their phenotype, resulting in a longer time in peripheral circulation with increased splenic clearance, potentially a strategy to maintain a clinically and immunologically silent low parasitemia [11]. In this study, we identified individuals infected at the end of the transmission season in The Gambia, determined how long these infections remained detectable during the dry season, and explored the related host and parasite factors.

## METHODS

### Study Design

Climate in The Gambia is characterized by a short rainy season and a long dry season. Malaria transmission follows the same pattern, starting in July or August and lasting until December, with little or no clinical cases during the dry season. In December 2016, all residents of 4 villages (Madina Samako, Sendebu, Njayel, Karanbada) located within 5 km of each other in the Upper River Region, eastern Gambia, were invited to have a finger prick blood sample collected and analyzed by VarATS quantitative polymerase chain reaction (qPCR) for *P falciparum* infection and confirmed that they had not received antimalarial treatment within the 2 weeks before sampling. The qPCR-positive individuals were invited for monthly samplings (venous blood draw of 5 to 8 mL), with qPCR and quantitative reverse-transcription (qRT)-PCR performed from the end of December until the end of the dry season (May), or until they either (1) became symptomatic and received treatment immediately, (2) cleared their infection (negative by qRT-PCR and/or VarATS qPCR 2 months in a row), or (3) withdrew from the study (Figure 1A). Subjects with an axillary temperature greater than 37.5°C were screened with a rapid diagnostic test (CareStart), and positives were treated with artemether-lumefantrine, the first-line treatment in The Gambia. Written informed consent was obtained from all participants; parents or legal guardians provided a written informed consent for minors (<18 years old). The study was approved by the Gambia Government/Medical Research Council Joint Ethics Committee (SCC 1476) and the London School of Hygiene

& Tropical Medicine ethics committee (Ref. 10982). In the 2 months preceding this study, the same villages were enrolled in an independent study (Claessens A et al, unpublished observations, December 2016) to monitor asymptomatic malaria infection via monthly VarATS qPCR surveys and symptomatic malaria infections by passive case detection and treatment by community-based nurses. Baseline infection status (confirmed qPCR negativity or history of treatment) of individuals with persistent or short-lived infections in October and November 2016 was similar between groups (persistent infections = 32% [7 of 22], short-lived infections [47% 8 of 17]; Fishers exact test,  $P = .49$ ) (Supplemental Table S1 and S2).

### Molecular Detection of Parasites


During the study, presence of *P falciparum* was assessed using VarATS qPCR as described in [23] from finger prick (start December screening) or venous blood samples (monthly, end of December to May). The parasite stages were quantified by qRT-PCR assays specific for ring stage parasites (*sbp-1*), male gametocytes (*PfMGET*), or female gametocytes (*CCp4*) as described before [24]. In these assays, parasite densities were determined using standard curves of purified parasite stages. Purified male and female gametocytes were generated using the PfDynGFP/P47mCherry reported line to enable sorting of the different sex gametocyte populations, as previously described [25]. Ring stage parasite standard curves were generated from NF54 parasite cultures after synchronization as detailed in [26]. Total parasite density was calculated as the sum of the male gametocytes, female gametocytes, and ring stage parasites quantified using the qRT-PCR assays. Samples were genotyped using *P falciparum* merozoite surface protein 2 (*msp2*) [27]. In brief, nucleic acid was extracted from 100  $\mu$ L whole blood, and 5  $\mu$ L was used in a nested PCR specific for *msp2* 3D7 and FC27 allelic families, followed by capillary electrophoresis to determine allelic size polymorphisms. Secondary PCR products were run on a 2% w/v agarose gel to check for bands within the correct size range (193 to 506 base pairs [bp]). Secondary PCR products were diluted, 2.5  $\mu$ L per sample was processed on an ABI 7500 fast (Applied Biosystems), and resulting chromatograms were analyzed using PeakScanner software version 2 (Applied Biosystems). To distinguish between true peaks and background signal or stutter peaks, a cutoff of 200 relative fluorescent units was applied, and fragment sizes must differ by more than 3 bp.

### Hemoglobin Quantification and Genotyping

Hemoglobin density was measured in December using a hemoglobin analyzer (HemoCue; AB Leo Diagnostics, Helsingborg, Sweden). Human hemoglobin S (HbS) and C (HbC) were genotyped using previously published methods [28].

### Serology

Immunoglobulin (Ig)G antibodies against 17 *P falciparum* antigens were quantified at baseline (late December 2016)



**Figure 1.** Study design and flow. (A) Illustration of study design (B) Study flow diagram. Subjects were screened in early December 2016, and asymptomatic parasite-positive individuals (by VarATS quantitative polymerase chain reaction [qPCR]) were selected at the end of the wet season (December 2016) and were recruited into a longitudinal study with monthly samples to determine duration of infection from end of December until the end of the dry season (May), or until they (1) cleared their infection (negative by PCR), or (2) became symptomatic and received treatment.

for each participant using a Luminex MAGPIX suspension bead array [29]: Circumsporozoite protein (CSP), Erythrocyte binding antigen (EBA140, EBA175, and EBA181); Glutamate rich protein 2 (GLURP-R2); Merozoite surface protein 1-19 (MSP1-19), Merozoite surface protein 2 (MSP2-ch150/9 [3D7 family allele] and MSP2-DD2 [FC27 family allele]); Apical membrane antigen 1 (AMA1), Reticulocyte binding protein homolog (RH2.2, RH4.2, RH5.1), Schizont egress antigen-1 (SEA1), Heat shock protein 40 (HSP40), Skeleton-binding protein 1 (SBP1), and Early transcribed membrane proteins 4 (ETRAPM4 Ag2) and 5 (ETRAPM5 Ag1). Full details of all

antigens are in [Supplementary Table 3](#). These antigens are either expressed during the asexual blood-stage (Etramp, PfSEA, HSP40, SBP1), involved in merozoite invasion (Rh, AMA1, EBA, MSP, GLURP) or localized on the surface of sporozoites (CSP). Serological analysis was conducted on serum samples collected in December, assayed at a dilution of 1:200. Secondary antibody was an R-phycoerythrin-conjugated goat antihuman IgG (109-116-098; Jackson ImmunoResearch, Ely, UK) diluted 1:200. Data are presented as median fluorescence intensity (median of individual bead fluorescence values for a given region/antigen specificity) adjusted for interplate variation in

background reactivity as previously described [29]. A sample was considered positive if the response was above background. The background response was calculated as the mean response of 4 negative controls plus 2 standard deviations. Negative controls were European, malaria-naïve donors.


### Statistical Analysis

Infections were classified as “short-lived” if they were cleared within 2 months, “persistent” if they remained detectable for 3–6 months, and “treated” if they became symptomatic and were treated. Data were analyzed with GraphPad Prism version 9. A normality test (D’Agostino–Pearson) was used to determine whether data were normally distributed. Unpaired *t* test was used to compare 2 groups of parametric data. Kruskal–Wallis with Dunn’s multiple comparison test was used to compare 3 or more groups of non-parametric data. Fisher’s exact test was used for contingency tables with small expected frequencies. Spearman’s correlation was used to analyze associations with non-parametric data, and Pearson’s correlation was used for parametric data.

## RESULTS

Malaria prevalence at the end of the transmission season (beginning of December 2016) was 8.0% (74 of 924), with children under 5 having lower prevalence (2.5%; 5 of 199) than children 5–15 years old (7.9%; 27 of 341) and individuals >15 years old (10.9%; 42 of 384). Complete follow-up data were obtained from 40 individuals, 2 did not complete follow up until negative by PCR, but they were parasite positive for at least 3 months, so they were included in the categorized analysis only (Figure 1A and B). Forty-one percent ( $n = 17$ ) of the subjects had short-lived infections (undetectable by January), 52% ( $n = 22$ ) had persistent infections (detectable by PCR for 3–6 months), and 3 infected subjects developed symptoms and were treated (7%, all children <15 years of age) (Figure 1B). Forty percent (16 of 40) of individuals infected in early December remained PCR positive until the end of the dry season, with most of these individuals (81.3%; 13 of 16) also carrying gametocytes at the end of the dry season (Figure 2).

No association between the sex of the individual and the duration of infection was found (Supplementary Table S2).




**Figure 2.** Duration of detectable parasite carriage in the blood during the dry season. Subjects ( $n = 42$ ) who were parasite positive by VarATS quantitative polymerase chain reaction (qPCR) in finger prick blood samples in December were followed monthly until PCR negative or treated. Two subjects who did not complete follow up were parasite positive for at least 3 months (and thus classified as persistent infections) and are excluded from the Kaplan–Meier graphs. (A) Number of subjects parasite positive each month ( $n = 40$ ). (B) Number of subjects positive each month by age category. (C) Asexual parasite densities over time in the persistent infections group, measured in venous blood samples by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) for ring stage parasite (*SBP-1*). (D) Total gametocyte densities (males + females) over time in the persistent infections group, measured in venous blood samples by qRT-PCR for male (*PfMGT*) and female (*CCP4*) gametocytes. Light gray lines show individual responses and the dark gray line shows the median response.

Mean hemoglobin concentration at the start of the dry season was 11.31 g/dL ( $n = 37$ ). HbAA was the most frequent hemoglobin type (75.7%; 28 of 37), followed by HbAS (21.6%; 8 of 37), and HbSS (2.7%; 1 of 37). There was no association between hemoglobin concentration (short-lived = 11.35, persistent = 11.18, treated = 11.30) or type and duration of carriage (Supplementary Table S4). Persistent infections were slightly more common in the 5- to 15-year-olds (63%; 12 of 19) than in the other age groups (<5 years, 0.0% [0 of 4]; >15 years, 53% [10 of 19]), but differences between groups were not statistically significant (Fisher's exact  $P = .074$ ) (Figure 2B), and there was no overall difference in the age of individuals with persistent or short-lived infections (Supplementary Figure S1) ( $P = .93$ ). More importantly, all children <5 years were offered 4 rounds of seasonal malaria chemoprevention during the transmission season with the last round being given in November. In persistent infections, asexual parasitemia and gametocytemia declined slowly over the season, with the median asexual parasitemia declining from 214 417 to 10 446 parasites/mL (Figure 2C) and gametocytemia declining from 1237 to 289 gametocytes/mL (Figure 2D). The ratio of male/female gametocytes was female biased (0.20; 95% confidence interval, 0.16–0.23). This sex ratio did not change over time (Supplementary Figure S2) and is similar to what was observed in other studies with transmissible infections [4].


At the start of the dry season, parasite density in persistent infections was significantly higher than in short-lived infections ( $P < .0001$  Kruskal-Wallis with Dunn's multiple comparison test) (Figure 3A), and duration of infection in months was significantly related to starting parasite density (Spearman's  $r = 0.86$ ,  $P < .0001$ ) (Figure 3B). Most persistent infections

(82%; 18 of 22) and only 1 of 17 short-lived infections had initial parasite densities above the theoretical limit of expert microscopy detection (10 p/μL) [30] (Figure 3A). At the end of December sampling (first monthly visit after screening), over half of the short-lived infections were undetectable by both the asexual parasite and gametocyte qRT-PCR assays (53%; 9 of 17), and 76% (13 of 17) did not have any asexual parasites detected, indicating these individuals had already cleared their infections in the first month. Whereas at the same time point, almost all persistent infections had asexual parasites (20 of 22) and/or gametocytes (20 of 22) at densities that could be quantified by the qRT-PCR assays.

Complexity of infection (the number of genetically distinct genotypes within a blood sample) was measured throughout the dry season using *msp2* genotyping (Figure 4A). In 21 of 115 samples, *msp2* genotype could not be determined, likely due to parasite densities being below the assay limit of detection. At the start of the dry season, most infections had less than 2 genotypes (80.5%; 33 of 41) and the median per subject was 1 (range, 1–8). Complexity of infection was significantly higher in the persistent than in the short-lived infections ( $P = .015$ , Kruskal-Wallis with Dunn's multiple comparison test). Higher complexity of infection (>2 genotypes) was only observed in persistent infections; all short-lived infections were monoclonal, except for 1 with 2 genotypes (Figure 4B). The number of genotypes at the start of the dry season also correlated with parasite density (Figure 4C). In every persistent infection, there was at least 1 *msp2* genotype detected repeatedly throughout the dry season, suggesting chronic infection with the same *P falciparum* strain as opposed to reinfection (Supplementary Figure S3).




**Figure 3.** Level of parasitemia at the beginning of the dry season and subsequent duration of detectable parasitemia. Total parasite density (sum of asexual parasites and male and female gametocytes) for each subject ( $n = 42$ ) by quantitative reverse-transcription polymerase chain reaction at the start of the dry season. (A) Total parasite density for each individual, by group. Groups compared by Kruskal-Wallis with Dunn's multiple comparison test. (B) Spearman's correlation between parasite density and duration of infection for the persistent and short-lived infection groups.



**Figure 4.** Genotypic complexity of parasite infection and persistent detectability through the dry season. The number of clones present in each individual was determined by *msp2* genotyping. (A) Number of clones for each individual over time, displayed by group. The black cross indicates where a sample was missing, and a “0” indicates the number of genotypes could not be determined. (B) Number of clones at the start of the dry season in the December or January sample, by group. For 7 subjects, there is no genotyping data available from December or January. Groups compared by Kruskal-Wallis with Dunn’s multiple comparison test. (C) Spearman’s correlation between number of clones and total parasite density at the start of the dry season (sum of asexual parasites and gametocytes determined by quantitative reverse-transcription polymerase chain reaction). Persistent infections (red circles), short-lived infections (black circles), and treated (filled circles). Vertical dashed line indicates the theoretical limit of expert microscopy detection.

To assess the role of host immunity in the persistence of *P falciparum* infection, antibodies were measured at the start of the dry season using a multiplex bead-based assay with a panel of 17 *P falciparum* antigens. There was a trend for higher *P falciparum*-specific antibody responses against 13 of the 17

antigens in subjects who developed persistent infections compared with those with short-lived infections ( $P = .02$ ) (Figure 5A and B). The 3 Rh family antigens (Rh2, Rh4.2, Rh5.1) were among the 4 most discriminatory antigens, with higher antibody levels associated with persistent infections, although



**Figure 5.** Antibody levels to a panel of *Plasmodium falciparum* antigens in relation to duration of detectable infection in the dry season. Antibody responses were measured to a panel of 17 *P. falciparum* antigens using a multiplex bead-based assay. (A) Panels show the individual subject responses to each antigen, by short-lived or persistent infection group, ordered by decreasing differences between the 2 groups. Dashed line indicates average background response. (B) Sum of the ranked response to all 13 upregulated antigens by group. (C) Breadth of the response to all 17 antigens, defined as the number of antigens each individual responded to above background by group. (D) Spearman's correlation between age and sum of the ranked response to all 17 antigens (treated, gray filled circles). (E) Number of antigens each individual responded to above background by age group. Box plots show the median with the whiskers indicating the minimum and maximum. Groups in (B) and (C) compared by unpaired *t* test.

only Rh5.1 reached statistical significance ( $P = .03$ ). Of the other individual antigens, only PfSEA and GLURP ( $P = .01$ ,  $P = .04$ , respectively) were significantly associated with subsequent duration of infection (persistent versus short-lived). Individuals with persistent infections tended to respond to more antigens (above background response) than those with short-lived infections ( $P = .07$ ) (Figure 5C). The magnitude of total *P. falciparum*-specific antibody response to all antigens was significantly correlated with age (Spearman's  $r = 0.39$ ,  $P = .03$ ) (Figure 5D), and there was also a trend for increased breadth of response with age (Figure 5E).

## DISCUSSION

In this study, 40% of individuals infected at the end of the wet season remained asymptotically infected until the end of the dry season, demonstrating the considerable silent reservoir of malaria that exists to restart the next transmission season in The Gambia. Individuals with persistent infections had higher starting parasite densities, often with multiclonal infections, and higher *P. falciparum*-specific antibody responses, suggesting that prior malaria exposure is important to maintain the human reservoir of malaria. Targeting these infections may significantly reduce such a



reservoir and thus the capacity of starting the next transmission season.

In areas of seasonal malaria transmission, understanding who maintains the parasite reservoir during the dry season may inform control interventions to reduce this reservoir and thereby the resurgence of malaria in the subsequent transmission season [1]. In our study setting, only 8% of village residents had detectable parasites at the end of the transmission season, and towards the end of the dry season the prevalence fell to 3%. In our modestly sized study population, we observed no clear relationship between subject age and duration of parasite carriage, although all persistent infections were found in those above 5 years of age. In general, the number of children under 5 infected at the end of the wet season was low compared with other age groups, possibly reflecting the levels of protective immunity, with younger children being more likely to develop symptoms when infected [7], or the impact of seasonal malaria chemoprevention [31] that is implemented in the study area.

Responses to our panel of 17 *P falciparum* antigens tested were generally low [18], highlighting the generally low level of malaria exposure in the area. Individuals with persistent infections tended to have higher and broader *P falciparum*-specific antibody responses than those with short-lived infections, a finding consistent with previous studies in seasonal settings [11, 12]. In Mali, asymptotically infected children had higher levels of *P falciparum*-specific antibodies than children with clinical malaria [13], whereas higher age (and thus cumulative exposure) was associated with longer duration of asymptomatic infection in Malawi [32], Uganda, and Ghana [14, 33]. In our study, we also observed a relationship between age and increasing magnitude and breadth of the immune responses, but this correlation was relatively weak. This supports earlier reports of marked heterogeneity in malaria exposure in The Gambia [3, 34]. In the context of our current findings, we hypothesize that this heterogeneity results in some individuals being more likely to experience repeated infections, resulting in higher levels of immunity and thus increased ability to sustain chronic asymptomatic parasite carriage, whereas age per se is not a strong determinant of immunity.

Each persistent infection had at least 1 unique genotype that was repeatedly observed, indicating infection persistence. High complexity of infection at the beginning of the dry season was associated with longer duration of asymptomatic carriage, consistent with other studies [35, 36]. This could either be due to multiple clones being received from a single mosquito bite [37], or by the accumulation of clones over time in those who harbor infections for a prolonged period. Complexity of infection and parasite density were also strongly correlated in this study. This could be partly explained by the difficulty of detecting all parasite clones when density is low and falling below the detection limit of the assay [38]. Our estimates of clonal complexity were based on MSP-2 genotyping. Although alternative genotyping

methods are available, these do not always improve sensitivity [39–41], even at low parasite densities. It is therefore unlikely that an alternative method would have resulted in different conclusions. Higher parasite density, multiclonal infections were more likely to persist throughout the dry season. This could indicate infection persistence simply reflects a longer period to clear a larger parasite biomass, although we did not observe clear declines in parasite densities during the dry season among persisting infections. The fact that short-lived infections had lower parasite densities could suggest these infections may have been carried longer and were already on the path to clearance [14]. Although this is a plausible factor for explaining our findings, available data before our cohort inception indicate that a similar proportion of individuals with both persisting and short-lived infections were either confirmed PCR negative or received curative treatment 1–2 months before the current study (Supplementary Table S1 and S2). We thus conclude that similar proportions of persistent and short-lived infections were acquired very recently. In addition to the explanations of higher parasite biomass or shorter infection age, parasites in persistent infections may be (epi)genetically programmed to survive longer, and/or genetically different from those in short-lived infections, potentially with a less virulent phenotype or slower parasite multiplication rate. This hypothesis is consistent with a recent study from Mali, where similar parasite populations were present in the wet and dry seasons. However, parasites in the dry season were transcriptionally different from those present in the wet season, and they were able to adapt their phenotype to secure longer circulation and reduced sequestration, resulting in increased splenic clearance and lower but persistent parasitemia [11].

## CONCLUSIONS

Our study was limited by the small sample size, largely governed by the decreasing malaria prevalence in the area [3]. However, we were able to demonstrate that the dry season reservoir of malaria largely comprised school aged children and adults who have likely experienced repeated infections. More importantly, persistent infections could potentially be identified at the start of the dry season, given that they were associated with higher initial parasite densities. Our findings confirm ongoing gametocyte production in chronic infections. Future studies may address the infectivity of these infections to mosquitoes and, more importantly for malaria control, determine whether clearing infections that are present at the start of the dry season results in a meaningful reduction in malaria burden in the next transmission season.

## Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Supplementary materials consist of data provided by the author that are published to benefit the

reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

## Notes

**Acknowledgments.** We thank Julia Mwesigwa and all field-workers for sample collection.

**Financial support.** This work was funded by grants from the Netherlands Organization for Scientific Research (Vidi fellowship NWO 016.158.306) and the Bill & Melinda Gates Foundation (INDIE OPP1173572), the joint MRC/LSHTM fellowship, and the French National Research Agency (18-CE15-0009-01). Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

**Potential conflicts of interest.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

## References

1. Babiker HA. Unstable malaria in Sudan: the influence of the dry season. *Plasmodium falciparum* population in the unstable malaria area of eastern Sudan is stable and genetically complex. *Trans R Soc Trop Med Hyg* **1998**; 92:585–9.
2. Ouedraogo AL, Goncalves BP, Gnome A, et al. Dynamics of the human infectious reservoir for malaria determined by mosquito feeding assays and ultrasensitive malaria diagnosis in Burkina Faso. *J Infect Dis* **2016**; 213:90–9.
3. Mwesigwa J, Okebe J, Affara M, et al. On-going malaria transmission in The Gambia despite high coverage of control interventions: a nationwide cross-sectional survey. *Malar J* **2015**; 14:314.
4. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. *Nat Rev Microbiol* **2014**; 12:833–40.
5. Ashley EA, White NJ. The duration of *Plasmodium falciparum* infections. *Malar J* **2014**; 13:500.
6. Hamad AA, El Hassan IM, El Khalifa AA, Ahmed GI, Abdelrahim SA, Theander TG, Arnot DE. Chronic *Plasmodium falciparum* infections in an area of low intensity malaria transmission in the Sudan. *Parasitology* **2000**; 120:447–56.
7. Andolina C, Rek JC, Briggs J, et al. Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. *Lancet Infect Dis* **2021**; 21:3099.
8. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. *Nat Med* **1999**; 5:340–3.
9. Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria morbidity in children and level of *Plasmodium falciparum* transmission in Africa. *Lancet* **1997**; 349:1650–4.
10. Baird JK. Host age as a determinant of naturally acquired immunity to *Plasmodium falciparum*. *Parasitol Today* **1995**; 11:105–11.
11. Andrade CM, Fleckenstein H, Thomson-Luque R, et al. Increased circulation time of *Plasmodium falciparum* underlies persistent asymptomatic infection in the dry season. *Nat Med* **2020**; 26:1929–40.
12. Portugal S, Tran TM, Ongoiba A, et al. Treatment of chronic asymptomatic *Plasmodium falciparum* infection does not increase the risk of clinical malaria upon reinfection. *Clin Infect Dis* **2017**; 64:645–53.
13. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to *Plasmodium falciparum* before and after a malaria season by protein microarray. *Proc Natl Acad Sci USA* **2010**; 107:6958–63.
14. Briggs J, Teyssier N, Nankabirwa JI, et al. Sex-based differences in clearance of chronic *Plasmodium falciparum* infection. *Elife* **2020**; 9:1–14.
15. Gonzales SJ, Reyes RA, Braddom AE, Batugedara G, Bol S, Bunnik EM. Naturally acquired humoral immunity against *Plasmodium falciparum* malaria. *Front Immunol* **2020**; 11:594653.
16. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. *Nat Immunol* **2008**; 9:725–32.
17. Rono J, Osier FH, Olsson D, et al. Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic *Plasmodium falciparum* infections and protection against clinical malaria. *Clin Infect Dis* **2013**; 57:1409–16.
18. Wu L, Mwesigwa J, Affara M, et al. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia. *BMC Med* **2020**; 18:304.
19. Achan J, Reuling IJ, Yap XZ, et al. Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a *Plasmodium falciparum* controlled human infection. *Clin Infect Dis* **2020**; 70:2544–52.
20. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. *Lancet Infect Dis* **2012**; 12:457–68.
21. White NJ. Anaemia and malaria. *Malar J* **2018**; 17:371.
22. Akiyama T, Pongvongsa T, Phrommala S, et al. Asymptomatic malaria, growth status, and anaemia among children in Lao People's Democratic Republic: a cross-sectional study. *Malar J* **2016**; 15:499.

23. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of *Plasmodium falciparum* by amplification of multi-copy subtelomeric targets. *PLoS Med* **2015**; 12:e1001788.
24. Meerstein-Kessel L, Andolina C, Carrio E, et al. A multiplex assay for the sensitive detection and quantification of male and female *Plasmodium falciparum* gametocytes. *Malar J* **2018**; 17:441.
25. Lasonder E, Rijpma SR, van Schaijk BC, et al. Integrated transcriptomic and proteomic analyses of *P. falciparum* gametocytes: molecular insight into sex-specific processes and translational repression. *Nucleic Acids Res* **2016**; 44:6087–101.
26. Stone W, Sawa P, Lanke K, et al. A molecular assay to quantify male and female *Plasmodium falciparum* gametocytes: results from 2 randomized controlled trials using primaquine for gametocyte clearance. *J Infect Dis* **2017**; 216:457–67.
27. Mueller I, Schoepflin S, Smith TA, et al. Force of infection is key to understanding the epidemiology of *Plasmodium falciparum* malaria in Papua New Guinean children. *Proc Natl Acad Sci U S A* **2012**; 109:10030–5.
28. Grignard L, Mair C, Curry J, et al. Bead-based assays to simultaneously detect multiple human inherited blood disorders associated with malaria. *Malar J* **2019**; 18:14.
29. Wu L, Hall T, Ssewanyana I, et al. Optimisation and standardisation of a multiplex immunoassay of diverse *Plasmodium falciparum* antigens to assess changes in malaria transmission using sero-epidemiology. *Wellcome Open Res* **2019**; 4:26.
30. Bejon P, Andrews L, Hunt-Cooke A, Sanderson F, Gilbert SC, Hill AV. Thick blood film examination for *Plasmodium falciparum* malaria has reduced sensitivity and underestimates parasite density. *Malar J* **2006**; 5:104.
31. Ahmad A, Prom A, Bradley J, et al. Gametocyte carriage after seasonal malaria chemoprevention in *Plasmodium falciparum* infected asymptomatic children. *Malar J* **2021**; 20:169.
32. Buchwald AG, Sorkin JD, Sixpence A, et al. Association between age and *Plasmodium falciparum* infection dynamics. *Am J Epidemiol* **2019**; 188:169–76.
33. Bretscher MT, Maire N, Felger I, Owusu-Agyei S, Smith T. Asymptomatic *Plasmodium falciparum* infections may not be shortened by acquired immunity. *Malar J* **2015**; 14:294.
34. Okebe J, Affara M, Correa S, et al. School-based country-wide seroprevalence survey reveals spatial heterogeneity in malaria transmission in the Gambia. *PLoS One* **2014**; 9:e110926.
35. Nassir E, Abdel-Muhsin AM, Suliaman S, et al. Impact of genetic complexity on longevity and gametocytogenesis of *Plasmodium falciparum* during the dry and transmission-free season of eastern Sudan. *Int J Parasitol* **2005**; 35:49–55.
36. Smith T, Beck HP, Kitua A, et al. Age dependence of the multiplicity of *Plasmodium falciparum* infections and of other malariological indices in an area of high endemicity. *Trans R Soc Trop Med Hyg* **1999**; 93(Suppl 1):15–20.
37. Nkhoma SC, Trevino SG, Gorena KM, et al. Co-transmission of related malaria parasite lineages shapes within-host parasite diversity. *Cell Host Microbe* **2020**; 27:93–103.e4.
38. Koepfli C, Schoepflin S, Bretscher M, et al. How much remains undetected? Probability of molecular detection of human *Plasmodia* in the field. *PLoS One* **2011**; 6:e19010.
39. Barry A, Bradley J, Stone W, et al. Higher gametocyte production and mosquito infectivity in chronic compared to incident *Plasmodium falciparum* infections. *Nat Commun* **2021**; 12:2443.
40. Gruenberg M, Lerch A, Beck HP, Felger I. Amplicon deep sequencing improves *Plasmodium falciparum* genotyping in clinical trials of antimalarial drugs. *Sci Rep* **2019**; 9:17790.
41. Lerch A, Koepfli C, Hofmann NE, et al. Development of amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria infections. *BMC Genomics* **2017**; 18:864.